Tamtam Try Tamtam free
DaVita Kidney Care logo

DaVita Kidney Care account plan

Kidney care community passion

At a glance

DaVita is a U.S. kidney care and dialysis provider with 2,657 U.S. centers, about 36% market share and FY2025 revenues of $13,643 million.

DaVita Inc. is a comprehensive kidney care provider and a leading U.S. dialysis provider, covering the kidney health journey from chronic kidney disease (CKD) to dialysis and transplant. At December 31, 2025 it ran 2,657 U.S. outpatient dialysis centers in 46 states and DC serving approximately 200,500 patients, had inpatient dialysis contracts with approximately 740 hospitals, and estimated an approximately 36% share of the U.S. dialysis market; it also operates 598 centers in 14 countries. FY2025 consolidated revenues were $13,643 million (+6.5%) and net income attributable to DaVita Inc. $746.8 million. It employs approximately 78,000 teammates, 72% in the U.S.; Berkshire Hathaway holds 45.0% of the shares.

Business units

Strategic priorities

Return to volume growth
Management targets a path back to 2% or greater treatment volume growth by 2029, through lower mortality and clinical performance; treatments grew 1.2% in Q3 2026 over Q3 2025.
Expanded hemodialysis rollout
After pilots in 150 centers for more than 10,000 patients, expanded HD with Nipro dialyzers is offered to the vast majority of eligible patients from November 2026, with mortality benefits expected from the back half of 2028.
Grow Integrated Kidney Care
More value-based contracts in CKCC and Medicare Advantage, and a CKD program with Humana covering approximately 10,000 CKD patients.
Technology modernisation
More than $1 billion invested over recent years to modernize the technology platform; tech spend grew more than 20% year-over-year and its growth will decelerate.
Growth through de novos and international
With the U.S. described as consolidated, growth comes more from new centers; international adjusted operating income is expected at approximately $135 million for 2026.
Capital return within leverage target
Share buybacks ($870 million in the first nine months of 2026) with leverage kept within a 3.0x-3.5x target.

Latest results

In Q3 2026 consolidated revenues were $3,578 million, adjusted operating income $561 million and net income attributable to DaVita Inc. $222.9 million, with diluted net income per share of $3.40 vs $2.04 in Q3 2025. For the first nine months revenues were $10,548 million (+5.2%) and adjusted operating income $1,622 million (+7.6%). U.S. dialysis revenue per treatment was $415.25 in Q3, pressured by lower commercial mix after enhanced ACA premium tax credits expired. Full-year 2026 guidance was narrowed to $2.175-$2.25 billion of adjusted operating income and $14.30-$15.20 of adjusted EPS, with free cash flow of $1 billion to $1.25 billion.

Investments and deals

Elara Caring minority stake
A $200 million minority investment in Elara Caring (home health, hospice, behavioral health and personal care), effective July 20, 2026, to offer dialysis-tailored home health services.
Technology platform
More than $1 billion invested to modernize technology, with benefits cited in mortality, revenue operations, labor productivity, IKC care management and pharmacy costs.
Share repurchases
$1,788 million of buybacks in FY2025 (14.9% net share count reduction) and $870 million in the first nine months of 2026; Berkshire Hathaway sells shares back to stay at 45.0%.
Mozarc Medical
A 50% kidney device venture with Medtronic; 2025 equity losses included $46.4 million of impairment and restructuring charges.

Challenges and risks

Commercial payor mix
Expiry of enhanced ACA premium tax credits hurt exchange enrollment and commercial mix: a $40 million headwind in 2026 and an expected $70 million in 2027.
Reimbursement below cost trends
CMS's 2027 final rule estimates a 2.7% average increase, but the CFO estimates a net 1.5%-2% impact; 90% of patients are government-covered.
Labor costs and union activity
Clinical labor wage rates rose approximately 3.8% in 2025, skilled clinical staff are short nationwide, and union petitions remain at California clinics.
Cybersecurity
An April 2025 incident exfiltrated PII and PHI, disrupted billing and new-patient intake, and cost approximately $25 million of charges in 2025.
Demand and competition
GLP-1 and SGLT2 therapies may slow CKD progression; competitors include Fresenius Medical Care and private-equity backed providers.

What leadership says

“a key milestone in our path back to 2% or greater volume growth by 2029”

Javier Rodriguez, Chief Executive Officer · Q3 2026 earnings call, October 29, 2026, on expanded HD

“we've invested more than $1 billion to modernize our technology platform”

Javier Rodriguez, Chief Executive Officer · Q3 2026 earnings call, October 29, 2026

“we are part of the solution, not the problem.”

Javier Rodriguez, Chief Executive Officer · Q3 2026 earnings call, October 29, 2026, on the HHS Kidney Care National Plan

“The net result is a rate increase that once again tracks below the cost trends for the industry.”

Javier Rodriguez, Chief Executive Officer · Q2 2026 earnings call, August 4, 2026, on the proposed 2027 CMS rule

Where a supplier can help

Clinical labor productivity
Tied to the labor cost challenge: staffing, scheduling and training tools for a labor-intensive network of about 2,657 U.S. centers.
Cybersecurity and data protection
Tied to the April 2025 incident that exfiltrated PII and PHI: security, monitoring and resilience for billing and patient intake systems.
Revenue cycle and payor analytics
Tied to the commercial payor mix challenge and the technology modernisation priority: collections, eligibility and payor-mix analytics.
Value-based care tooling
Tied to the IKC growth priority: predictive analytics, care coordination and claims analysis for CKCC, Medicare Advantage and the Humana CKD program.
Dialysis supplies and devices
Tied to the expanded HD rollout: dialyzers, medical supplies and logistics as patient care costs per treatment rise.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like DaVita Kidney Care?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about DaVita Kidney Care

What does DaVita do?

DaVita provides kidney care, mainly dialysis for patients with end stage kidney disease in U.S. outpatient centers, hospitals and at home, plus integrated kidney care and international dialysis operations.

What is DaVita's revenue?

FY2025 consolidated revenues were $13,643 million, up 6.5%. Revenues for the first nine months of 2026 were $10,548 million, up 5.2%.

How many employees does DaVita have?

Approximately 78,000 teammates at December 31, 2025, about 72% of them in the U.S.

Who leads DaVita?

Javier Rodriguez is Chief Executive Officer and Joel Ackerman is CFO.

What is DaVita's strategy?

Return to treatment volume growth of 2% or more by 2029 through clinical innovation such as expanded HD, grow integrated kidney care, modernize technology and expand through de novos and international centers.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)